Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AMG 509 |
Synonyms | |
Therapy Description |
AMG 509 is a bispecific T-cell engager targeting STEAP1 and CD3, potentially resulting in increased immune response against STEAP1-expressing tumors cells (PMID: 37861452). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AMG 509 | AMG509|AMG-509|Xaluritamig | CD3 Antibody 99 | AMG 509 is a bispecific T-cell engager targeting STEAP1 and CD3, potentially resulting in increased immune response against STEAP1-expressing tumors cells (PMID: 37861452). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06555796 | Phase I | AMG 509 | Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer | Recruiting | USA | AUS | 0 |